NCT05221398Recruiting
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Adjuvant Immune CheckPoint InhibitoRs Based ThErapy in PostoperatiVe HEpatocellular CarciNoma: a ProspecTive Real-world Study
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 14 Jan 2022
- Start date
- 3 Mar 2019
- Primary completion date
- 18 Dec 2030
- Lead sponsor
- Guangxi Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05221398
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 3 Mar 2019 to the primary completion date, 18 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receive neoadjuvant immune checkpoint inhibitors therapy.
Who the study is looking for
- Underwent curative hepatectomy;
- Diagnosis of HCC was confirmed by postoperative histopathology;
- Liver function Child-Pugh A or B;
- Performance status score 0 or 1
- With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jian-Hong Zhong Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.